BR112023019720A2 - Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit - Google Patents
Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kitInfo
- Publication number
- BR112023019720A2 BR112023019720A2 BR112023019720A BR112023019720A BR112023019720A2 BR 112023019720 A2 BR112023019720 A2 BR 112023019720A2 BR 112023019720 A BR112023019720 A BR 112023019720A BR 112023019720 A BR112023019720 A BR 112023019720A BR 112023019720 A2 BR112023019720 A2 BR 112023019720A2
- Authority
- BR
- Brazil
- Prior art keywords
- growth
- combination
- compounds
- inhibiting
- bacteria
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title abstract 3
- 241000894006 Bacteria Species 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- -1 rifamycin analog compounds Chemical class 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 108010059993 Vancomycin Proteins 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 abstract 2
- 229960003165 vancomycin Drugs 0.000 abstract 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 2
- 229930189077 Rifamycin Natural products 0.000 abstract 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229960003292 rifamycin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166597P | 2021-03-26 | 2021-03-26 | |
| PCT/US2022/021922 WO2022204499A1 (en) | 2021-03-26 | 2022-03-25 | Rifamycin analogs in combination with vancomycin and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019720A2 true BR112023019720A2 (pt) | 2024-01-23 |
Family
ID=81308077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019720A BR112023019720A2 (pt) | 2021-03-26 | 2022-03-25 | Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240189319A1 (https=) |
| EP (1) | EP4313060B1 (https=) |
| JP (1) | JP2024511165A (https=) |
| KR (1) | KR20230162654A (https=) |
| CN (1) | CN117098540A (https=) |
| AU (1) | AU2022246161A1 (https=) |
| BR (1) | BR112023019720A2 (https=) |
| CA (1) | CA3213382A1 (https=) |
| CL (1) | CL2023002840A1 (https=) |
| CO (1) | CO2023013406A2 (https=) |
| ES (1) | ES3017798T3 (https=) |
| IL (1) | IL307220A (https=) |
| MX (1) | MX2023011328A (https=) |
| WO (1) | WO2022204499A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024221162A1 (zh) * | 2023-04-24 | 2024-10-31 | 丹诺医药(苏州）有限公司 | 化合物预防关节假体周围感染的方法 |
| KR20260012505A (ko) | 2024-07-18 | 2026-01-27 | 이화여자대학교 산학협력단 | 기계 학습을 이용한 반코마이신 초회 투여량 적합성 판단 시스템 및 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118955710A (zh) * | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| PH12021551476A1 (en) * | 2018-12-21 | 2022-04-25 | Regeneron Pharma | Rifamycin analogs and antibody-drug conjugates thereof |
-
2022
- 2022-03-25 ES ES22716719T patent/ES3017798T3/es active Active
- 2022-03-25 AU AU2022246161A patent/AU2022246161A1/en not_active Abandoned
- 2022-03-25 IL IL307220A patent/IL307220A/en unknown
- 2022-03-25 BR BR112023019720A patent/BR112023019720A2/pt unknown
- 2022-03-25 MX MX2023011328A patent/MX2023011328A/es unknown
- 2022-03-25 KR KR1020237036447A patent/KR20230162654A/ko active Pending
- 2022-03-25 US US18/552,303 patent/US20240189319A1/en active Pending
- 2022-03-25 CA CA3213382A patent/CA3213382A1/en active Pending
- 2022-03-25 EP EP22716719.4A patent/EP4313060B1/en active Active
- 2022-03-25 CN CN202280025168.0A patent/CN117098540A/zh active Pending
- 2022-03-25 JP JP2023558774A patent/JP2024511165A/ja active Pending
- 2022-03-25 WO PCT/US2022/021922 patent/WO2022204499A1/en not_active Ceased
-
2023
- 2023-09-25 CL CL2023002840A patent/CL2023002840A1/es unknown
- 2023-10-09 CO CONC2023/0013406A patent/CO2023013406A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240189319A1 (en) | 2024-06-13 |
| CN117098540A (zh) | 2023-11-21 |
| CO2023013406A2 (es) | 2023-10-30 |
| AU2022246161A1 (en) | 2023-10-12 |
| KR20230162654A (ko) | 2023-11-28 |
| ES3017798T3 (en) | 2025-05-13 |
| CA3213382A1 (en) | 2022-09-29 |
| WO2022204499A1 (en) | 2022-09-29 |
| MX2023011328A (es) | 2023-12-14 |
| CL2023002840A1 (es) | 2024-03-15 |
| EP4313060A1 (en) | 2024-02-07 |
| IL307220A (en) | 2023-11-01 |
| JP2024511165A (ja) | 2024-03-12 |
| EP4313060B1 (en) | 2025-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| CL2022002919A1 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| CO2018010966A2 (es) | Nuevos derivados de pirazolopirimidina | |
| CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| BR112013005426A2 (pt) | "composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação." | |
| BRPI1012219C1 (pt) | produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina | |
| CR20200148A (es) | Compuestos monobactámicos cromados para el tratamiento de infecciones bacterianas | |
| BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
| CU23366B7 (es) | Oxazolidinonas substituidas para terapia de combinación | |
| CO2020001242A2 (es) | Dihidrooxadiazinonas | |
| BR112017027719A8 (pt) | Composto, zwitterion, composição farmacêutica, e, uso de um composto | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| MX2022001803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas. | |
| BR112023019720A2 (pt) | Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| MX2022011565A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| BR112022008938A2 (pt) | Derivados de 1-aminossulfonil-2-carboxipirrol como inibidores de metalo-beta-lactamase | |
| CR20230510A (es) | Compuestos de lactivicina, su preparación y uso como agentes antibacterianos | |
| MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
| BR112023026356A2 (pt) | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c | |
| BR112013008037A2 (pt) | compostos multivalentes como tratamento antibiótico | |
| CL2021002430A1 (es) | Formulación de tableta vaginal | |
| BR112022024117A2 (pt) | Derivados de 7-pirazol-5-il-indol macrocíclico como inibidores de mcl-1 |